Immuno-Oncology Market Is Predicted To Reach US$ 111.64 Billion By 2034, Expanding At A CAGR Of 16.5% Fact.MR
Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...
BioSpace11d
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
Business Wire4d
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Progr…
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, ...
Healio5d
‘There is a whole other world out there’: Beyond CAR-T therapies for autoimmune diseases
Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)Findings in ...
Zacks Investment Research on MSN1d
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
Labcorp LH recently entered into an agreement with OPKO Health, Inc. OPK, a multinational biopharmaceutical and diagnostics company, to acquire select assets of the latter’s wholly owned subsidiary, ...